Taylor HS, et al. - The intent behind this research, was to assess self-reported improvements in endometriosis-associated pelvic pain (dysmenorrhea and non-menstrual pelvic pain), dyspareunia (DYSP), and quality of life (QoL) in women treated with elagolix for at least 12-months (M). The physicians demonstared that the improvements in pain symptoms and QoL observed in the placebo-controlled, 6M, pivotal studies were maintained over 12M of elagolix treatment.